OBJECTIVE: To explore the potential utility of hepatitis C virus (HCV) seroprevalence as a biomarker for injection risk, and herpes simplex virus-2 (HSV-2) as a biomarker for sexual risk among injecting drug users (IDUs). We examined the relationships between HCV and HIV and between HSV-2 and HIV among injecting drug users in New York City relative to the large-scale implementation of syringe exchange in the mid-1990s. METHODS: 397 injecting drug users were recruited from a drug detoxification program in New York from 2005 to 2007. Informed consent was obtained, a questionnaire covering demographics, drug use and HIV risk was administered. Blood samples were tested for antibody to HIV, HCV and HSV-2. RESULTS: Among all subjects, HIV prevalence was 17%, HCV prevalence 72% and HSV-2 prevalence 48%. Among IDUs who began injecting before 1995, HIV was 28%, HCV serostatus was strongly associated with HIV serostatus (AOR=8.96, 95% CI 1.16-69.04) and HSV-2 serostatus was not associated with HIV serostatus (AOR=1.31, 95% CI 0.64-2.67). Among subjects who began injecting in 1995 or later, HIV was 6%, HCV was not associated with HIV (AOR=1.04, 95% CI 0.27-4.08) and HSV-2 serostatus was strongly related to HIV serostatus (AOR=10.71, 95% CI 1.18-97.57). CONCLUSIONS: HCV and HSV-2 HCV and HSV-2 may provide important new tools for monitoring evolving HIV epidemics among IDUs. Reconsideration of the current CDC hierarchical transmission risk classification system may also be warranted.
OBJECTIVE: To explore the potential utility of hepatitis C virus (HCV) seroprevalence as a biomarker for injection risk, and herpes simplex virus-2 (HSV-2) as a biomarker for sexual risk among injecting drug users (IDUs). We examined the relationships between HCV and HIV and between HSV-2 and HIV among injecting drug users in New York City relative to the large-scale implementation of syringe exchange in the mid-1990s. METHODS: 397 injecting drug users were recruited from a drug detoxification program in New York from 2005 to 2007. Informed consent was obtained, a questionnaire covering demographics, drug use and HIV risk was administered. Blood samples were tested for antibody to HIV, HCV and HSV-2. RESULTS: Among all subjects, HIV prevalence was 17%, HCV prevalence 72% and HSV-2 prevalence 48%. Among IDUs who began injecting before 1995, HIV was 28%, HCV serostatus was strongly associated with HIV serostatus (AOR=8.96, 95% CI 1.16-69.04) and HSV-2 serostatus was not associated with HIV serostatus (AOR=1.31, 95% CI 0.64-2.67). Among subjects who began injecting in 1995 or later, HIV was 6%, HCV was not associated with HIV (AOR=1.04, 95% CI 0.27-4.08) and HSV-2 serostatus was strongly related to HIV serostatus (AOR=10.71, 95% CI 1.18-97.57). CONCLUSIONS:HCV and HSV-2HCV and HSV-2 may provide important new tools for monitoring evolving HIV epidemics among IDUs. Reconsideration of the current CDC hierarchical transmission risk classification system may also be warranted.
Authors: V Anna Gyarmathy; Nan Li; Karin E Tobin; Irving F Hoffman; Nikolai Sokolov; Julia Levchenko; Julia Batluk; Andrei A Kozlov; Andrei P Kozlov; Carl A Latkin Journal: AIDS Behav Date: 2011-01
Authors: Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas Journal: J Infect Dis Date: 2011-01-31 Impact factor: 5.226
Authors: Kate Shannon; Thomas Kerr; M-J Milloy; Aranka Anema; Ruth Zhang; Julio S G Montaner; Evan Wood Journal: AIDS Date: 2011-10-23 Impact factor: 4.177
Authors: Daniel J Escudero; Mark N Lurie; Kenneth H Mayer; Caleb Weinreb; Maximilian King; Sandro Galea; Samuel R Friedman; Brandon D L Marshall Journal: AIDS Date: 2016-10-23 Impact factor: 4.177
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Holly Hagan; David C Perlman; Salaam Semaan Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman Journal: Drug Alcohol Depend Date: 2015-04-13 Impact factor: 4.492
Authors: Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308